What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?

Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6. As per data from Benzinga Pro, the Wall Street estimates sales of $13.7 billion, with adjusted EPS of $4.94.

In January, just before the JP Morgan healthcare conference, Eli Lilly announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.50 billion.

The company’s expected 2024 revenue is $400 million, or about 3%, below the guidance range issued during the third-quarter earnings. The guidance includes approximately $3.5 billion for Mounjaro and $1.9 billion for Zepbound.

Also Read: Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts

Analysts are tracking Eli Lilly’s expected increase in sales and profit in the ...

Full story available on Benzinga.com